A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer (Q45893794)
Jump to navigation
Jump to search
scientific article published on 4 November 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer |
scientific article published on 4 November 2015 |
Statements
1 reference
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer (English)
1 reference
Jan Baughman
1 reference
Deryk Loo
1 reference
Francine Chen
1 reference
Paul Moore
1 reference
Ezio Bonvini
1 reference
James Vasselli
1 reference
Jon Wigginton
1 reference
Roger Cohen
1 reference
4 November 2015
1 reference
3
1 reference
Suppl 2
1 reference
P177-P177
1 reference
Identifiers
1 reference